Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Dec;20(4):360-7.
doi: 10.4104/pcrj.2011.00064.

Procalcitonin-guided antibiotic treatment of respiratory tract infections in a primary care setting: are we there yet?

Affiliations
Review

Procalcitonin-guided antibiotic treatment of respiratory tract infections in a primary care setting: are we there yet?

Rune Aabenhus et al. Prim Care Respir J. 2011 Dec.

Abstract

Clinical signs of infection do not allow for correct identification of bacterial and viral aetiology in acute respiratory infections. A valid tool to assist the clinician in identifying patients who will benefit from antibiotic therapy, as well as patients with a potentially serious infection, could greatly improve patient care and limit excessive antibiotic prescriptions. Procalcitonin is a new marker of suspected bacterial infection that has shown promise in guiding antibiotic therapy in acute respiratory tract infections in hospitals without compromising patient safety. Procalcitonin concentrations in primary care are low and can be used primarily to rule out serious infection. However, procalcitonin measurement should not be used as the sole basis for clinical decisions; clinical skills are prerequisites for the correct use of this new tool in practice. At present there is no point-of-care test for procalcitonin with acceptable precision, severely hampering its application in primary care. This article reviews the physiology of procalcitonin, describes the assays available for its measurement, evaluates the present evidence from primary care on its use to identify correctly patients who are likely to benefit from antibiotic treatment and to rule out serious infections, and comments on further research to determine a future role for procalcitonin in primary care.

PubMed Disclaimer

Conflict of interest statement

Rune Aabenhus: None declared

Jens-Ulrik Stæhr Jensen: Received an unrestricted grant in 2008 from Brahms Diagnostica, Heningsdorf, Germany, and has participated in symposia sponsored by Brahms Diagnostica, Heningsdorf, Germany, the last being held more than one year ago.

Comment in

Publication types

MeSH terms